{'fraction_non_alphanumeric': 0.031487513572204126, 'fraction_numerical': 0.004343105320304018, 'mean_word_length': 5.5587188612099645, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Invited Commentary. The Royalty of Evidence: The Randomized Control Trials

In the last issue of the journal we came across a propensity matched analysis of stage I non-small cell lung cancer (NSCLC) patients treated either by means of surgery or by stereotactic body radiotherapy (SBRT)[1]. The authors report equal local control survival, regional control survival, loco-regional control survival, distant control survival (DC), diseasefree survival and progression-free survival, however SBRT patients had worse overall survival rate compared to surgical patients. This paper is interesting and also thought-provoking. Despite the in depth analysis of this paper, all the included studies were based on retrospective data. Most of the referenced papers quote survival times at 2–3 years, not the standard 5-year survival. The authors report favorable overall survival for the surgical group, irrespective of matching and support the imperative need that their conclusions should be strengthened by randomized control trials (RCTs). This report reflects the ongoing debate between SBRT and surgery. Stage I non-small cell lung cancer (NSCLC) is potentially curable, and surgery is considered the standard of care for patients with minimal comorbidities and good performance status. Notably, the 5-year overall survival (OS) has been reported to be around 60% in some studies [2]. Nevertheless, a significant portion of these patients are poor candidates for surgery due comorbidities such as chronic obstructive pulmonary disease (COPD), cardiovascular disease or poor physical status. Stereotactic ablative radiotherapy (SABR) or stereotactic body radiotherapy (SBRT) was employed as an alternative treatment strategy for cancer patients. This method, which is a noninvasive treatment alternative to surgery, adopts modern radiotherapeutic